TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33706247

Group type: EXPERIMENTAL
Intervention: Phenobarbitone withdrawal group (n = 112)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Phenobarbitone continued group (n = 109)
Number of subjects: 221
Study: 36292193

Group type: EXPERIMENTAL
Intervention: Expiratory technique
Number of subjects: 280

Group type: COMPARATOR
Intervention: Tracheal suction
Number of subjects: 280
Study: 32847461

Group type: EXPERIMENTAL
Intervention: Combined omega-3 and Korean red ginseng supplementation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 34364670

Group type: EXPERIMENTAL
Intervention: Rhythm control with amiodarone/cardioversion
Number of subjects: 523

Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 523
Study: 33236662

Group type: EXPERIMENTAL
Intervention: Moderate fixed-dose hydroxyurea (20 mg/kg/day)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Low fixed-dose hydroxyurea (10 mg/kg/day)
Number of subjects: 220
Study: 35510925

Group type: EXPERIMENTAL
Intervention: Game-based phone application
Number of subjects: 248

Group type: COMPARATOR
Intervention: Standard training (video and paper copy)
Number of subjects: 248
Study: 32079861

Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Carvedilol plus Simvastatin
Number of subjects: 220
Study: 34263351

Group type: EXPERIMENTAL
Intervention: Bilateral vestibulopathy patients
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 37
Study: 32629535

Group type: EXPERIMENTAL
Intervention: Radiofrequency thoracic sympathectomy (Group TS)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham (Group Sham)
Number of subjects: 66
Study: 34183348

Group type: EXPERIMENTAL
Intervention: Pilot trials with specified progression criteria
Number of subjects: 160

Group type: COMPARATOR
Intervention: Peer reviewer reports
Number of subjects: 160
Study: 33857678

Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuroimaging assessments (MRI & PET)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall trial costs
Number of subjects: 0
Study: 35090033

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AE, n=21)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Combined exercise training (CE, n=20)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Unaccustomed exercise
Number of subjects: 84

Group type: COMPARATOR
Intervention: Systemic inflammation
Number of subjects: 84

Group type: COMPARATOR
Intervention: Physical performance measures
Number of subjects: 84

Group type: COMPARATOR
Intervention: Tumour necrosis factor-α
Number of subjects: 84

Group type: COMPARATOR
Intervention: Interleukin-6
Number of subjects: 84
Study: 34320708

Group type: EXPERIMENTAL
Intervention: 2% lidocaine for nerve blockage
Number of subjects: 126

Group type: COMPARATOR
Intervention: Intravenous injection of 50 mg dexketoprofen
Number of subjects: 126
Study: 32487875

Group type: EXPERIMENTAL
Intervention: DNA methylation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multivariate predictive modeling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mendelian randomization
Number of subjects: 0
Study: 35158325

Group type: EXPERIMENTAL
Intervention: 5-point method loading conditions
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2-point method loading conditions
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 5-point method excluding the data point most declining the coefficient of determination
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (sport students)
Number of subjects: 30
Study: 33619896

Group type: EXPERIMENTAL
Intervention: Carillon device
Number of subjects: 83

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 83
Study: 32717295

Group type: EXPERIMENTAL
Intervention: 7 mg transdermal nicotine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 39
Study: 35933417

Group type: EXPERIMENTAL
Intervention: We-PAP (couples-based sleep health intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Information Control (IC)
Number of subjects: 0
Study: 33438206

Group type: EXPERIMENTAL
Intervention: Continuation of medications with limited benefit in hospice patients (cancer and non-cancer diagnoses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prescribing oral anticoagulants in the emergency department
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conducting electronic medication reconciliation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensification of antihypertensive medications
Number of subjects: 0
Study: 34409538

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 214
Study: 34244982

Group type: EXPERIMENTAL
Intervention: Variance minimisation (VM) procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random assignment procedure
Number of subjects: 0
Study: 36472543

Group type: EXPERIMENTAL
Intervention: Hybrid Closed Loop (HCL)
Number of subjects: 302
Study: 33199081

Group type: EXPERIMENTAL
Intervention: Combination of continuous wave CO2 laser and fractional ablative CO2 laser (Group 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fractional ablative CO2 laser alone (Group 2)
Number of subjects: 40
Study: 33078725

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam administered by parents
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intranasal midazolam administered by doctors
Number of subjects: 60
Study: 35392881

Group type: EXPERIMENTAL
Intervention: T-shaped toothbrush
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional toothbrush
Number of subjects: 100
Study: 33301652

Group type: EXPERIMENTAL
Intervention: Standard computer-assisted cognitive training (CACT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CACT enhanced with music (CACT+A)
Number of subjects: 25
Study: 32252049

Group type: EXPERIMENTAL
Intervention: Lactofem oral probiotic capsule (500 mg daily for 2 months)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 70
Study: 35470105

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (50,000 IU weekly for 8 weeks)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo tablets (identical for 8 weeks)
Number of subjects: 62
Study: 34229752

Group type: EXPERIMENTAL
Intervention: i-PRF
Number of subjects: 346

Group type: COMPARATOR
Intervention: Blood clot
Number of subjects: 346
Study: 34688374

Group type: EXPERIMENTAL
Intervention: Toripalimab plus celecoxib (n=17)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Toripalimab monotherapy (n=17)
Number of subjects: 34
Study: 34335740

Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.3 mg/kg bolus after induction, followed by 0.2 mg/kg/hr infusion for up to 24 hours)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (standard therapy)
Number of subjects: 35
Study: 35077207

Group type: EXPERIMENTAL
Intervention: Autologous conditioned serum (ACS) dressing
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (NS) dressing
Number of subjects: 30
Study: 32012051

Group type: EXPERIMENTAL
Intervention: Once-a-day pain reporting
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Twice-a-day pain reporting
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Once-a-week pain reporting
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: As-and-when pain reporting
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Qualitative findings from interviews
Number of subjects: 14
Study: 35352134

Group type: EXPERIMENTAL
Intervention: Western diet‐like high‐carbohydrate meal (WDHC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Western diet‐like high-fat meal (WDHF)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mediterranean diet‐like meal (MED)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High inflammation group (CRP ≥ 2.0 mg/L)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low inflammation group (CRP < 2.0 mg/L)
Number of subjects: 60
Study: 35142162

Group type: COMPARATOR
Intervention: Low EGFR expression in HPV16 positive tumors (89.29%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PIK3CA mutations in HPV16 positive (7.14%) and HPV negative (2.5%) cancers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low expression of APOBEC3B in HPV16 positive patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: APOBEC3B, Akt, and pAkt(Thr308) levels in HPV negative patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: pAkt(Thr308) levels in HPV negative patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low T stage, low pAkt(Thr308) expression, active HPV16 infection, and female gender
Number of subjects: 0
Study: 32208108

Group type: EXPERIMENTAL
Intervention: Multidisciplinary cooperative clinical trials program for advanced Hodgkin's disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cooperative clinical trials program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hodgkin's disease trial
Number of subjects: 0
Study: 36195807

Group type: EXPERIMENTAL
Intervention: efavirenz (activator, orally)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: rifampicin (inducer, orally)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: oral voriconazole (inhibitor)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: intravenous voriconazole (inhibitor)
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo control
Number of subjects: 24
Study: 33637230

Group type: EXPERIMENTAL
Intervention: BGG492 (selurampanel) 100mg TID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BGG492 (selurampanel) 50mg TID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32127545

Group type: EXPERIMENTAL
Intervention: Intranasal administration (standard nasal spray)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal administration (nebulizer)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous administration
Number of subjects: 0
Study: 35713224

Group type: EXPERIMENTAL
Intervention: AI (DENTAL MONITORING®)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: AIHC (DENTAL MONITORING® + human counseling)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 53
Study: 32188915

Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg/day for 7 days
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 33843086

Group type: EXPERIMENTAL
Intervention: 20G fenestrated catheter
Number of subjects: 26

Group type: COMPARATOR
Intervention: 18G standard catheter
Number of subjects: 26
Study: 35533701

Group type: EXPERIMENTAL
Intervention: Triple-drug regimen (ivermectin 200 μg/kg, diethylcarbamazine 6 mg/kg, albendazole 400 mg)
Number of subjects: 4563

Group type: COMPARATOR
Intervention: Two-drug regimen (diethylcarbamazine 6 mg/kg, albendazole 400 mg)
Number of subjects: 4563

Group type: EXPERIMENTAL
Intervention: Triple-drug regimen
Number of subjects: 4563

Group type: COMPARATOR
Intervention: Two-drug regimen
Number of subjects: 4563
Study: 33434451

Group type: EXPERIMENTAL
Intervention: 4 monthly videoconference‐tailored coaching sessions with an advanced practice nurse or social worker, participation in patient appointments via videoconference, access to a website designed for DCGs.
Number of subjects: 302

Group type: COMPARATOR
Intervention: Access to the DCG website only.
Number of subjects: 302

Group type: COMPARATOR
Intervention: Access to the DCG website and participation in patient appointments via videoconference, but no coaching sessions.
Number of subjects: 302
Study: 32933498

Group type: EXPERIMENTAL
Intervention: Preoperative induction chemotherapy (2 cycles of FLOT: 5‐FU, leucovorin, oxaliplatin, docetaxel) followed by preoperative radiochemotherapy (oxaliplatin weekly, 5‐FU plus concurrent fractioned radiotherapy to a dose of 45 Gy)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Preoperative chemotherapy alone (4 cycles of FLOT)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Combined chemotherapy/radiochemotherapy treatment
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Preoperative induction chemotherapy (2 cycles of FLOT) followed by preoperative radiochemotherapy
Number of subjects: 340

Group type: COMPARATOR
Intervention: Preoperative chemotherapy with FLOT alone
Number of subjects: 340
Study: 36475294

Group type: EXPERIMENTAL
Intervention: liraglutide 3 mg/day
Number of subjects: 135

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 135
Study: 32506882

Group type: EXPERIMENTAL
Intervention: Probiotic mixture containing Bifidobacterium animalis subsp. lactis BB-12 and Enterococcus faecium L3
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group of 109 healthy, untreated subjects
Number of subjects: 94
Study: 34184369

Group type: EXPERIMENTAL
Intervention: Video consultation invitation (default option)
Number of subjects: 1481

Group type: EXPERIMENTAL
Intervention: Active choice invitation (choose between in-person or video)
Number of subjects: 1481

Group type: COMPARATOR
Intervention: In-person invitation (default option)
Number of subjects: 1481
Study: 33528516

Group type: EXPERIMENTAL
Intervention: 10-mg/d Vericiguat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15-mg/d Vericiguat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35620203

Group type: EXPERIMENTAL
Intervention: Fascia iliac compartment block (FICB)
Number of subjects: 231

Group type: COMPARATOR
Intervention: General anesthesia (control group)
Number of subjects: 231
Study: 34341196

Group type: EXPERIMENTAL
Intervention: Manual separation followed by topical antibiotic ointment application for 1 week with local hygiene
Number of subjects: 48
Study: 35917993

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) administered prior to initial acquisition of a predictive learning task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS)
Number of subjects: 0
Study: 32844292

Group type: EXPERIMENTAL
Intervention: Native cholecalciferol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 30
Study: 34994708

Group type: EXPERIMENTAL
Intervention: App-based relaxation exercises (including audio-based autogenic training, mindfulness meditation, or guided imagery)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Usual care and app for data entry only (Control)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: App-based relaxation exercises
Number of subjects: 220
Study: 34147923

Group type: EXPERIMENTAL
Intervention: taVNS at 2 mA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control stimulation at 2 mA
Number of subjects: 0
Study: 32553252

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement
Number of subjects: 435

Group type: COMPARATOR
Intervention: Surgical valve replacement
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 435
Study: 35351196

Group type: COMPARATOR
Intervention: CAF + PL
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: BJ + CAF
Number of subjects: 16
Study: 34043103

Group type: EXPERIMENTAL
Intervention: Eribulin as first- or second-line chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 33485468

Group type: EXPERIMENTAL
Intervention: 3 µg with Algel-IMDG
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: 6 µg with Algel-IMDG
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: 6 µg with Algel
Number of subjects: 375

Group type: COMPARATOR
Intervention: Algel only (control)
Number of subjects: 375
Study: 32441331

Group type: EXPERIMENTAL
Intervention: Moderate‐ to high‐intensity aerobic and strength exercise program
Number of subjects: 494

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 494
Study: 34324377

Group type: EXPERIMENTAL
Intervention: Digital intervention (text messaging)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (medical facts)
Number of subjects: 21
Study: 33054742

Group type: EXPERIMENTAL
Intervention: Revised scripted lesson plans for HIV and sexual content in life orientation curriculum (implemented in 55 schools).
Number of subjects: 2802

Group type: COMPARATOR
Intervention: Control group (50 schools).
Number of subjects: 2802
Study: 34110839

Group type: EXPERIMENTAL
Intervention: TAU + ApBM (12-session approach bias modification training)
Number of subjects: 729

Group type: COMPARATOR
Intervention: TAU-only (treatment as usual)
Number of subjects: 729

Group type: EXPERIMENTAL
Intervention: TAU + ApBM
Number of subjects: 729

Group type: COMPARATOR
Intervention: TAU-only
Number of subjects: 729
Study: 33667194

Group type: EXPERIMENTAL
Intervention: Low-dose testosterone (T)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Aromatase inhibitor letrozole (Lz)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: All boys (combined results)
Number of subjects: 26
Study: 35297176

Group type: EXPERIMENTAL
Intervention: Self-affirming implementation intentions (S-AII)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Non-affirming implementation intentions (active control)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Mere goal intentions (non-active control)
Number of subjects: 130
Study: 32859334

Group type: EXPERIMENTAL
Intervention: Mediterranean dietary pattern (MDP)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 357
Study: 35277406

Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 0
Study: 33619855

Group type: EXPERIMENTAL
Intervention: Local infusion of ropivacaine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 18
Study: 616701079

Group type: EXPERIMENTAL
Intervention: Music intervention (listening to music for 30 minutes)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control (wearing headphones with no music for 30 minutes)
Number of subjects: 85
Study: 35897025

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 120

Group type: COMPARATOR
Intervention: Artificial Tears (AT)
Number of subjects: 120
Study: 33789432

Group type: EXPERIMENTAL
Intervention: Dry Needling Combined With Guideline‐Based Physical Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Guideline‐Based Physical Therapy
Number of subjects: 0
Study: 32549148

Group type: EXPERIMENTAL
Intervention: Exposure to Second Hand Smoking (SHS)
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Knowledge about SHS
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Response to SHS exposure
Number of subjects: 789
Study: 36480102

Group type: EXPERIMENTAL
Intervention: One Anastomosis Gastric Bypass (OAGB)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Sleeve Gastrectomy (SG)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Both OAGB and SG
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: OAGB
Number of subjects: 335

Group type: COMPARATOR
Intervention: SG
Number of subjects: 335
Study: 34600589

Group type: EXPERIMENTAL
Intervention: IL-6 receptor antagonists (IL-6RAs)
Number of subjects: 860

Group type: EXPERIMENTAL
Intervention: Combination therapy (IL-6RAs and steroids)
Number of subjects: 860

Group type: COMPARATOR
Intervention: Steroids
Number of subjects: 860
Study: 32339359

Group type: EXPERIMENTAL
Intervention: PTSD Coach (n=33)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Treatment as usual (TAU; n=31)
Number of subjects: 64
Study: 33724264

Group type: EXPERIMENTAL
Intervention: CRT-D (Cardiac Resynchronization and Defibrillator Therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CRT-P (CRT Alone)
Number of subjects: 0
Study: 33068691

Group type: COMPARATOR
Intervention: EX + placebo (EX0)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: EX + 500 mg/day resveratrol (EX500)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: EX + 1000 mg/day resveratrol (EX1000)
Number of subjects: 60
Study: 32247660

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (10 mg/kg) plus acetaminophen (15 mg/kg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Acetaminophen (15 mg/kg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ibuprofen (10 mg/kg)
Number of subjects: 90
Study: 33197226

Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg every 2 weeks
Number of subjects: 499

Group type: COMPARATOR
Intervention: Continued chemotherapy
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Avelumab in PD-L1-positive population (n = 54)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Avelumab in exploratory analysis of PD-L1-positive population (n = 137)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Continued chemotherapy in exploratory analysis of PD-L1-positive population (n = 137)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 499
Study: 32345730

Group type: EXPERIMENTAL
Intervention: NF1 germline mutations
Number of subjects: 29
Study: 34510020

Group type: EXPERIMENTAL
Intervention: Machine-based resistance training protocol (3 times a week for 6 weeks)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 11
Study: 32172171

Group type: EXPERIMENTAL
Intervention: PSA stimulation
Number of subjects: 13

Group type: COMPARATOR
Intervention: VIM stimulation
Number of subjects: 13
Study: 35072758

Group type: EXPERIMENTAL
Intervention: Cilostazol (100 mg daily) + Sertraline (100 mg daily)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo + Sertraline (100 mg daily)
Number of subjects: 54
Study: 34708642

Group type: EXPERIMENTAL
Intervention: Qingre Huatan formulae + Western Medicine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional Western Medicine only
Number of subjects: 60
Study: 34988730

Group type: EXPERIMENTAL
Intervention: Intradermal tranexamic acid injection combined with low fluence Q-switched Nd:YAG laser
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intradermal tranexamic acid injection alone
Number of subjects: 40
Study: 33308035

Group type: EXPERIMENTAL
Intervention: High-intensity exercise for 20 minutes
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Self-reported engagement in moderate-to-vigorous physical activity
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (viewed a time matched video)
Number of subjects: 150